Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer.

dc.contributor.author

Russell, Shonagh

dc.contributor.author

Lim, Felicia

dc.contributor.author

Peters, Pamela N

dc.contributor.author

Wardell, Suzanne E

dc.contributor.author

Whitaker, Regina

dc.contributor.author

Chang, Ching-Yi

dc.contributor.author

Previs, Rebecca A

dc.contributor.author

McDonnell, Donald P

dc.date.accessioned

2022-10-01T14:15:43Z

dc.date.available

2022-10-01T14:15:43Z

dc.date.issued

2022-08

dc.date.updated

2022-10-01T14:15:41Z

dc.description.abstract

Despite advances in surgery and targeted therapies, the prognosis for women with high-grade serous ovarian cancer remains poor. Moreover, unlike other cancers, immunotherapy has minimally impacted outcomes in patients with ovarian cancer. Progress in this regard has been hindered by the lack of relevant syngeneic ovarian cancer models to study tumor immunity and evaluate immunotherapies. To address this problem, we developed a luciferase labeled murine model of high-grade serous ovarian cancer, STOSE.M1 luc. We defined its growth characteristics, immune cell repertoire, and response to anti PD-L1 immunotherapy. As with human ovarian cancer, we demonstrated that this model is poorly sensitive to immune checkpoint modulators. By developing the STOSE.M1 luc model, it will be possible to probe the mechanisms underlying resistance to immunotherapies and evaluate new therapeutic approaches to treat ovarian cancer.

dc.identifier

cancers14174219

dc.identifier.issn

2072-6694

dc.identifier.issn

2072-6694

dc.identifier.uri

https://hdl.handle.net/10161/25943

dc.language

eng

dc.publisher

MDPI AG

dc.relation.ispartof

Cancers

dc.relation.isversionof

10.3390/cancers14174219

dc.subject

STOSE

dc.subject

high-grade serous

dc.subject

immune profiling

dc.subject

immunotherapy

dc.subject

intraperitoneal

dc.subject

murine

dc.subject

ovarian cancer

dc.subject

ovarian intrabursal

dc.subject

syngeneic

dc.title

Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer.

dc.type

Journal article

duke.contributor.orcid

Peters, Pamela N|0000-0002-6259-3054

duke.contributor.orcid

Wardell, Suzanne E|0000-0002-5792-1447

duke.contributor.orcid

Chang, Ching-Yi|0000-0003-2115-9574

duke.contributor.orcid

Previs, Rebecca A|0000-0001-8087-9120

duke.contributor.orcid

McDonnell, Donald P|0000-0002-7331-4700

pubs.begin-page

4219

pubs.issue

17

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Pharmacology & Cancer Biology

pubs.organisational-group

Medicine

pubs.organisational-group

Obstetrics and Gynecology

pubs.organisational-group

Medicine, Endocrinology, Metabolism, and Nutrition

pubs.organisational-group

Obstetrics and Gynecology, Gynecologic Oncology

pubs.organisational-group

Duke Cancer Institute

pubs.publication-status

Published

pubs.volume

14

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer.pdf
Size:
1.85 MB
Format:
Adobe Portable Document Format
Description:
Published version